Jonathan Pacella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan Pacella has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Sarosh Percy Batlivala
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2 shared publications Abe E. Sahmoun
Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Grand Forks, USA
1 shared publicationAmr Matoq
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
1 shared publication- Audrey Lane
Department: Internal Medicine and Pediatrics, 986270 Nebraska Medical Center, Omaha NE 68198-670
1 shared publication - Benjamin S. Mantell
Division of Cardiology, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
1 shared publication - Bryan H. Goldstein
University of Pittsburgh School of Medicine
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8) , 105510
Catheter-Directed Recombinant Tissue Plasminogen Activator for Treatment of Aortic Root and Coronary Artery Thrombosis in Single Ventricle Patients: A Case Series
- 16 July 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8) , 105510
Open AccessCatheter-Directed Recombinant Tissue Plasminogen Activator for Treatment of Aortic Root and Coronary Artery Thrombosis in Single Ventricle Patients: A Case Series
- Open Access
- 19 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 663-673
Pressure‐Wire Guided Hybrid Branch Pulmonary Artery Band Placement for Palliation of Single Ventricle and Critical Congenital Cardiac Lesions
Background: Historically, bilateral pulmonary artery band (PAB) placement was guided by pulmonary blood flow surrogates including systemic blood pressure (BP) and arterial saturation. These metrics alone may result in suboptimal bPAB placement. We perform a hybrid PAB (hPAB) procedure employing pressure‐wire assessment to evaluate pulmonary hemodynamics and guide the procedure. Methods: Single‐center retrospective study of consecutive patients that underwent hybrid bPAB procedure between August 2015 and May 2022. Procedures involved main pulmonary artery (PA) angiography and selective PA pressure‐wire assessment. Aortic pressure and arterial saturation were recorded. Results: Twenty‐three patients underwent hPAB procedure. Median procedure time was 190 min [range 122−480 min]. Ten patients underwent 15 total adjustments to a PA band, 6 (40%) based solely on pressure assessment with inappropriately low and non‐pulsatile pressures. Five patients underwent 13 PA interventions after hPAB, 12 (92%) were transcatheter and 1 (8%) operative. Two patients underwent transcatheter angioplasty of a branch PA band in the interstage period while 4 underwent a total of 10 catheter‐based PA interventions after the subsequent operation, at a median of 7 days [range 7−270 days] post‐operatively. Two patients underwent PA stent implant. Branch PA Z ‐scores were normal at birth and remained normal at most recent follow‐up for survivors (46 months), with final PA symmetry (smaller/larger PA area × 100) of 91% ± 9%. Conclusions: Pressure‐wire data identified more patients with overly restrictive bands during hybrid bPAB procedures than traditional markers alone. Many survivors required future PA intervention, and all demonstrated appropriate bilateral PA growth and symmetry.
- 19 May 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 663-673
Open AccessPressure‐Wire Guided Hybrid Branch Pulmonary Artery Band Placement for Palliation of Single Ventricle and Critical Congenital Cardiac Lesions
Background: Historically, bilateral pulmonary artery band (PAB) placement was guided by pulmonary blood flow surrogates including systemic blood pressure (BP) and arterial saturation. These metrics alone may result in suboptimal bPAB placement. We perform a hybrid PAB (hPAB) procedure employing pressure‐wire assessment to evaluate pulmonary hemodynamics and guide the procedure. Methods: Single‐center retrospective study of consecutive patients that underwent hybrid bPAB procedure between August 2015 and May 2022. Procedures involved main pulmonary artery (PA) angiography and selective PA pressure‐wire assessment. Aortic pressure and arterial saturation were recorded. Results: Twenty‐three patients underwent hPAB procedure. Median procedure time was 190 min [range 122−480 min]. Ten patients underwent 15 total adjustments to a PA band, 6 (40%) based solely on pressure assessment with inappropriately low and non‐pulsatile pressures. Five patients underwent 13 PA interventions after hPAB, 12 (92%) were transcatheter and 1 (8%) operative. Two patients underwent transcatheter angioplasty of a branch PA band in the interstage period while 4 underwent a total of 10 catheter‐based PA interventions after the subsequent operation, at a median of 7 days [range 7−270 days] post‐operatively. Two patients underwent PA stent implant. Branch PA Z ‐scores were normal at birth and remained normal at most recent follow‐up for survivors (46 months), with final PA symmetry (smaller/larger PA area × 100) of 91% ± 9%. Conclusions: Pressure‐wire data identified more patients with overly restrictive bands during hybrid bPAB procedures than traditional markers alone. Many survivors required future PA intervention, and all demonstrated appropriate bilateral PA growth and symmetry.
- Open Access
- 1 December 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (12) , 2706-2708
Catastrophic antiphospholipid antibody syndrome associated with ischaemic cardiomyopathy
We report the case of a 16-year-old female with previously diagnosed bilateral sub-segmental pulmonary emboli who presented in cardiogenic shock from depressed biventricular function with cardiac MRI demonstrating concern for microvascular coronary injury. She was ultimately diagnosed with catastrophic antiphospholipid antibody syndrome-induced ischaemic cardiomyopathy, potentially associated with an underlying autoimmune connective tissue disease.
- 1 December 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (12) , 2706-2708
Open AccessCatastrophic antiphospholipid antibody syndrome associated with ischaemic cardiomyopathy
We report the case of a 16-year-old female with previously diagnosed bilateral sub-segmental pulmonary emboli who presented in cardiogenic shock from depressed biventricular function with cardiac MRI demonstrating concern for microvascular coronary injury. She was ultimately diagnosed with catastrophic antiphospholipid antibody syndrome-induced ischaemic cardiomyopathy, potentially associated with an underlying autoimmune connective tissue disease.
- 19 May 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (8) , 1865-1872
A cross-sectional analysis of infant-driven and traditional feeding outcomes for neonatal intensive care unit infants
Objective The goal of this study was to assess the impact of infant-driven feeding (IDF) compared to traditional feeding protocols in promoting earlier successful feeding outcomes. Study design We performed a cross-sectional analysis of infants admitted to a level three neonatal intensive care unit (NICU) over a 2-year period. We compared infants fed with the traditional protocol to those under the IDF protocol. Results Infants in the IDF group were younger at first feed (p < 0.001). There was no difference in age at nasogastric (NG) tube removal or at discharge, length of stay, or percentage breastfeeding at discharge. There were no differences in outcomes within two subgroups born at <35 and <32 weeks gestation, respectively. Conclusion The IDF program led to earlier initiation of oral feeding. However, this did not lead to earlier NG tube removal or discharge, a shorter length of stay, or increase in the rates of breastfeeding.
- 19 May 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (8) , 1865-1872
A cross-sectional analysis of infant-driven and traditional feeding outcomes for neonatal intensive care unit infants
Objective The goal of this study was to assess the impact of infant-driven feeding (IDF) compared to traditional feeding protocols in promoting earlier successful feeding outcomes. Study design We performed a cross-sectional analysis of infants admitted to a level three neonatal intensive care unit (NICU) over a 2-year period. We compared infants fed with the traditional protocol to those under the IDF protocol. Results Infants in the IDF group were younger at first feed (p < 0.001). There was no difference in age at nasogastric (NG) tube removal or at discharge, length of stay, or percentage breastfeeding at discharge. There were no differences in outcomes within two subgroups born at <35 and <32 weeks gestation, respectively. Conclusion The IDF program led to earlier initiation of oral feeding. However, this did not lead to earlier NG tube removal or discharge, a shorter length of stay, or increase in the rates of breastfeeding.
- Open Access
- 19 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
IgG4-Related Retroperitoneal Fibrosis: A Rare Association With Riedel’s Thyroiditis
Idiopathic retroperitoneal fibrosis is a rare fibro-inflammatory disease that can be associated with other IgG4-related diseases (IgG4-RDs). It is exceedingly uncommon to encounter this condition in a patient with Riedel’s thyroiditis (RT), another disease in the IgG4-RD family. We present the case of a 53-year-old man with a history of RT who presented for severe localized lower abdominal and suprapubic pain due to obstructive uropathy from extensive retroperitoneal fibrosis. The biopsy of the mass demonstrated fibro-inflammatory tissue, and its immunohistochemistry was notable for IgG4-positive plasma cells. This case highlights the challenge associated with the diagnosis and management of this rare manifestation of IgG4-RD. In a patient with a history of any form of IgG4-RDs, providers should be vigilant for any signs or symptoms that suggest the development of fibrosis in other organs.
- 19 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Open AccessIgG4-Related Retroperitoneal Fibrosis: A Rare Association With Riedel’s Thyroiditis
Idiopathic retroperitoneal fibrosis is a rare fibro-inflammatory disease that can be associated with other IgG4-related diseases (IgG4-RDs). It is exceedingly uncommon to encounter this condition in a patient with Riedel’s thyroiditis (RT), another disease in the IgG4-RD family. We present the case of a 53-year-old man with a history of RT who presented for severe localized lower abdominal and suprapubic pain due to obstructive uropathy from extensive retroperitoneal fibrosis. The biopsy of the mass demonstrated fibro-inflammatory tissue, and its immunohistochemistry was notable for IgG4-positive plasma cells. This case highlights the challenge associated with the diagnosis and management of this rare manifestation of IgG4-RD. In a patient with a history of any form of IgG4-RDs, providers should be vigilant for any signs or symptoms that suggest the development of fibrosis in other organs.
- Open Access
Schlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma
Schlafen 12 (SLFN12) is an intermediate human Schlafen that induces differentiation in enterocytes, prostate, and breast cancer. We hypothesized that SLFN12 influences lung cancer biology. We investigated survival differences in high versus low SLFN12-expressing tumors in two databases. We then adenovirally overexpressed SLFN12 (AdSLFN12) in HCC827, H23, and H1975 cells to model lung adenocarcinoma (LUAD), and in H2170 and HTB-182 cells representing lung squamous cell carcinoma (LUSC). We analyzed proliferation using a colorimetric assay, mRNA expression by RT-qPCR, and protein by Western blot. To further explore the functional relevance of SLFN12, we correlated SLFN12 with seventeen functional oncogenic gene signatures in human tumors. Low tumoral SLFN12 expression predicted worse survival in LUAD patients, but not in LUSC. AdSLFN12 modulated expression of SCGB1A1, SFTPC, HOPX, CK-5, CDH1, and P63 in a complex fashion in these cells. AdSLFN12 reduced proliferation in all LUAD cell lines, but not in LUSC cells. SLFN12 expression inversely correlated with expression of a myc-associated gene signature in LUAD, but not LUSC tumors. SLFN12 overexpression reduced c-myc protein in LUAD cell lines but not in LUSC, by inhibiting c-myc translation. Our results suggest SLFN12 improves prognosis in LUAD in part via a c-myc-dependent slowing of proliferation.
Open AccessSchlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma
Schlafen 12 (SLFN12) is an intermediate human Schlafen that induces differentiation in enterocytes, prostate, and breast cancer. We hypothesized that SLFN12 influences lung cancer biology. We investigated survival differences in high versus low SLFN12-expressing tumors in two databases. We then adenovirally overexpressed SLFN12 (AdSLFN12) in HCC827, H23, and H1975 cells to model lung adenocarcinoma (LUAD), and in H2170 and HTB-182 cells representing lung squamous cell carcinoma (LUSC). We analyzed proliferation using a colorimetric assay, mRNA expression by RT-qPCR, and protein by Western blot. To further explore the functional relevance of SLFN12, we correlated SLFN12 with seventeen functional oncogenic gene signatures in human tumors. Low tumoral SLFN12 expression predicted worse survival in LUAD patients, but not in LUSC. AdSLFN12 modulated expression of SCGB1A1, SFTPC, HOPX, CK-5, CDH1, and P63 in a complex fashion in these cells. AdSLFN12 reduced proliferation in all LUAD cell lines, but not in LUSC cells. SLFN12 expression inversely correlated with expression of a myc-associated gene signature in LUAD, but not LUSC tumors. SLFN12 overexpression reduced c-myc protein in LUAD cell lines but not in LUSC, by inhibiting c-myc translation. Our results suggest SLFN12 improves prognosis in LUAD in part via a c-myc-dependent slowing of proliferation.